Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Phase 2

Active, not recruiting

Conditions: Advanced Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Adriamycin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Etoposide
Drug: Cyclophosphamide
Radiation: Radiation Therapy

First Posted Date: 2018-05-07

Last Posted Date: 2023-11-09

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 150

Registration Number: NCT03517137

Locations: 🇳🇱
Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands
🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇵🇱
Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland

and more 13 locations

A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Phase 1

Terminated

Conditions: Castration-resistant Prostate Cancer

Interventions: Biological: DCVac/PCa
Drug: Cyclophosphamide

First Posted Date: 2018-05-02

Last Posted Date: 2021-02-01

Lead Sponsor: SOTIO a.s.

Target Recruit Count: 5

Registration Number: NCT03514836

Locations: 🇨🇿
Fakultní nemocnice v Motole, Praha, Czechia

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Phase 2

Active, not recruiting

Conditions: B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-04-23

Last Posted Date: 2025-01-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 80

Registration Number: NCT03505762

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Phase 1

Terminated

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: BCMA-specific CAR-expressing T Lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Gamma-Secretase Inhibitor LY3039478
Other: Laboratory Biomarker Analysis
Other: Pharmacokinetic Study

First Posted Date: 2018-04-18

Last Posted Date: 2024-01-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 19

Registration Number: NCT03502577

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Phase 3

Terminated

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Paclitaxel
Drug: Dose-dense Doxorubicin or dose-dense Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2018-04-17

Last Posted Date: 2024-08-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2199

Registration Number: NCT03498716

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇦🇺
Royal Adelaide Hospital; Cancer Centre, Adelaide, South Australia, Australia

and more 361 locations

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

Phase 2

Conditions: Breast Cancer
Invasive Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Letrozole
Drug: leuprorelin

First Posted Date: 2018-04-13

Last Posted Date: 2018-04-13

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 114

Registration Number: NCT03497702

Locations: 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Phase 3

Completed

Conditions: Early Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Docetaxel
Drug: Paclitaxel
Drug: FDC of Pertuzumab and Trastuzumab SC
Drug: Pertuzumab IV
Drug: Trastuzumab IV
Drug: Trastuzumab SC
Procedure: Surgery
Radiation: Post-operative Radiotherapy
Drug: Hormone Therapy

First Posted Date: 2018-04-11

Last Posted Date: 2024-06-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 500

Registration Number: NCT03493854

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇯🇵
St. Luke's International Hospital, Tokyo, Japan
🇧🇪
Institut Jules Bordet, Anderlecht, Belgium

and more 104 locations

CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

Not Applicable

Terminated

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Cyclophosphamide
Drug: Methylprednisolone
Drug: Prednisone
Drug: Mycophenolate Mofetil

First Posted Date: 2018-04-10

Last Posted Date: 2021-07-21

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 49

Registration Number: NCT03492255

Locations: 🇧🇷
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
🇧🇷
Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia in Remission
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Biological: Inotuzumab Ozogamicin
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Ofatumumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-04-04

Last Posted Date: 2024-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT03488225

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3

Active, not recruiting

Conditions: Lymphoma
Myelodysplasia
Plasma Cell Disorder
Acute Myeloid Leukemia
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Myeloproliferative Disorder
Myelofibrosis

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Radiation: Total Body Irradiation
Drug: Tacrolimus
Drug: cellcept
Drug: g-csf
Procedure: Peripheral Blood Transplant

First Posted Date: 2018-03-29

Last Posted Date: 2024-07-23

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 21

Registration Number: NCT03480360

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy